Predictive Disease Analytics Market Trends Analysis Report 2025-2030: AI and Analytics Tools Gain Traction as Healthcare Systems Seek Cost Efficiency and Better Outcomes
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Predictive Disease Analytics Market Size, Share & Trends Analysis Report by Component (Hardware, Software & Services), Deployment (On-premise, Cloud-based), End Use, Region, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The Predictive Disease Analytics Market was valued at USD 3.0 Billion in 2024, and is projected to reach USD 10.2 Billion by 2030, rising at a CAGR of 22.70%
Predictive disease analytics refers to software solutions used by healthcare organizations, hospitals, and physicians to analyze and process patient data in order to provide data-driven, high-quality care, precise diagnostics, and individualized treatments. Predictive analytics is an advanced method to enhance patient outcomes in healthcare.
Additionally, predictive analytics solutions are used by healthcare providers to comprehend disease prevalence, disease management, risk management & trajectories, and to provide suitable medical care to patients for optimal outcomes. Healthcare providers use it to evaluate the risk rate to an individual's health as well as predict future outcomes in preparation. Its use at various levels to avoid unnecessary expenditure had also increased the utilization of this technology, which is anticipated to continue throughout the forecast period. As a result, the global predictive disease analytics market is expected to grow.Predictive analytics has played a significant part in combating COVID-19 problems, decreasing the incidence of poor outcomes for patients, and addressing resource management during the crisis. The massive amount of patient data produced during the outbreak not only provided analytics firms and the healthcare sector with data to properly analyze disease spread, but it also aided in resource allocation. Several institutions, including hospitals, was using predictive analytics to determine the probability of a patient developing severe symptoms, the trajectory of their infection/disease, and several other parameters. For instance, in 2020, researchers at the Cleveland Clinic in the U. S. created an automated analytics model that predicted an individual's chance of testing positive. Hence, propelling the market growth.The global market is expanding rapidly as a result of the increasing burden of chronic diseases, the emergence of personalized and evidence-based medicine, the growing need for increased efficiency in the healthcare sector, and the growing demand to reduce healthcare costs by eliminating unnecessary costs. As per the center for disease control, six out of every ten Americans have at least one chronic illness, such as heart disease or stroke, cancer, or diabetes. Hence, it will increase the product demand and further boost the market growth.Another important reason driving market growth is the use of evidence-based medicine to provide the right kind of treatment to the right patient. The utilization of Electronic Health Records (EHRs) for patient records has increased in recent years, with adoption of EHRs in the case of office-based doctors increasing from 42% in 2008 to nearly 88% in 2021 in the U. S. Healthcare predictive analytics makes use of EHRs to recommend the best course of action in the event of a medical treatment or medication. This not only greatly reduces patient costs but also leads to improved outcomes. The adoption of electronic health systems, analytics tools, and artificial intelligence (AI) are expected to drive market development. The expense of healthcare has risen over the years owing to the increasing burden of chronic diseases on a global level.The companies in the predictive disease analytics market are continuously expanding their product and services portfolio to accelerate the development of the product. For instance, in June 2022, Engagys LLC, a Health Consultant Company, announced the debut of a new affordable subscription service for healthcare systems, health plans, & healthcare technology leaders. Executive Advisory Services is intended to provide healthcare customer engagement practitioners with practical and actionable guidance, insights, and best practices that they can put to use immediately. This is expected to strengthen the company's position in predictive analytics solution and further boost the market growth.Predictive Disease Analytics Market Report Highlights
Cloud-based solutions are anticipated to have the highest CAGR during the forecast period. The ease of storage, inexpensive capital requirements, increased flexibility, and efficiency are attributed to its development.
On the basis of end user, payer segment dominated the market in 2023.Payers, such as insurance firms, health plan sponsors, as well as other third-party payers, are among the primary beneficiaries of predictive analytics in healthcare settings. Thus, boosting the segment growth.
Due to the rising prevalence of chronic diseases, greater awareness of preventive health and rising percentage of geriatric population in North America, the region had the largest market share.
Why Should You Buy This Report?
Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
Competitive Landscape: Explore the market presence of key players.
Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Attributes:
Report Attribute
Details
No. of Pages
80
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$3 Billion
Forecasted Market Value (USD) by 2030
$10.2 Billion
Compound Annual Growth Rate
22.7%
Regions Covered
Global
Predictive Disease Analytics Market Variables, Trends & Scope
Market Lineage Outlook
Parent market outlook
Related/ancillary market outlook
Market Driver Analysis
Rise in government initiatives and an increasing amount of money being invested in the healthcare industry
Technological advancements in AI and machine learning
Increasing prevalence of chronic diseases
Growing shift towards personalized medicine
Market Restraint Analysis
Growing data privacy concerns
Lack of skilled professionals
High implementation cost
Companies Featured
Oracle
Cerner Corporation
IBM
SAS
Allscripts Healthcare Solutions Inc.
MedeAnalytics, Inc.
Health Catalyst.
Apixio Inc
GE Healthcare (a division of General Electric Company)
Siemens Healthineers
For more information about this report visit https://www.researchandmarkets.com/r/uu9aic
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Predictive Disease Analytics Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'
Yahoo
an hour ago
- Yahoo
Best-ever map of the human genome sheds light on 'jumping genes,' 'junk DNA' and more
When you buy through links on our articles, Future and its syndication partners may earn a commission. Twenty-two years after the completion of the Human Genome Project, scientists have unveiled the most expansive catalog of human genetic variation ever compiled. Across two new papers published Wednesday (July 23) in the journal Nature, scientists sequenced the DNA of 1,084 people around the world. They leveraged recent technological advancements to analyze long stretches of genetic material from each person, stitched those fragments together and compared the resulting genomes in fine detail. The results deepen our understanding of "structural variants" within the human genome. Rather than affecting a single "letter" in DNA's code, such variations affect large chunks of the code — they may be deleted from or added to the genome, or encompass places where the DNA has been flipped around or moved to a different location. The studies have revealed "hidden" features of the human genome that were previously too technologically challenging to study, said Jan Korbel, the interim head of European Molecular Biology Laboratory (EMBL) Heidelberg, who is a co-author of both new papers. For instance, large portions of the genome contain codes that repeat over and over, and these were thought to be nonfunctional. "Some 20 years ago, we thought about this as 'junk DNA' — we gave it a very bad term," Korbel told Live Science. "There's more and more the realization that these sequences are not junk," and the new work sheds light on these long-maligned DNA sequences. Additionally, all of the data generated in the new studies are open access, so others in the field can now take "the findings, some of the tools we've developed and use them for their purposes to understand the genetic basis of disease," Korbel told Live Science. "I thoroughly believe that the advances that we're publishing in Nature today, a subset of these will also make it into diagnostics." Related: People's racial and ethnic identities don't reflect their genetic ancestry Over 1,000 genomes When the first draft of a "complete" human genome was published in 2003, it was actually missing about 15% of its sequence due to technological limitations of the time. In 2013, scientists managed to close that gap by about half. And finally, in 2022, the first "gapless" human genome was published. In 2023, researchers published the first draft of a human pangenome, which incorporated DNA from 47 people around the world, rather than predominantly being based on one person's DNA. And that same year, researchers published the first Y chromosome that had ever been sequenced from end to end, because the previous "gapless" genome was still missing the male sex chromosome. In the past few years, the field has continued to advance, thanks to new technologies and efforts to expand DNA sampling beyond populations of mostly European descent. Those advancements heralded the two papers published in Nature this week. In the first study, researchers sequenced the DNA of 1,019 people representing 26 populations across five continents. To analyze the DNA, the researchers collected "long reads," each composed of tens of thousands of base pairs; one base pair corresponds with one rung in the spiral ladder of a DNA molecule. "With short reads of around 100 base pairs, it is difficult to distinguish between genomic regions that look alike," explained study co-author Jesus Emiliano Sotelo-Fonseca, a doctoral student at the Centre for Genomic Regulation (CGR) in Barcelona, Spain. That's especially true in repetitive regions of the genome. "With longer reads, of around 20k base pairs, assigning each read to a unique position in the genome gets much easier," he told Live Science in an email. More than half of the new genomic variation uncovered in the study was found in those tricky repetitive regions, including in transposons, also known as jumping genes. Transposons can leap to different locations in the genome, copying and pasting their code. Sometimes, depending on where they land, they can destabilize the genome, introduce harmful mutations and contribute to diseases like cancer. "Our study reveals that some of these transposons can hijack regulatory sequences to boost their activity, contributing to understanding the biological mechanisms behind their mutagenicity," or ability to trigger mutations, study co-author Bernardo Rodríguez-Martín, an independent fellow at CGR and a former postdoc in Korbel's EMBL lab, told Live Science in an email. The jumping genes can essentially hitch a ride with certain regulatory molecules — long noncoding RNAs — and use that trick to make far more copies of themselves than they usually would. "That's a very surprising mechanism to us," Korbel said. Related: Scientists just discovered a new way cells control their genes From 95% to 99% The second study featured far fewer genomes — only 65 in total — but sequenced those genomes more comprehensively than the first study did. The first study captured about 95% of each genome analyzed, while the second study generated 99%-complete genomes. "It might sound like a small difference, but it's huge actually from the perspective of the genome scientist," Korbel said. "To get the last few percentages, it's a major achievement." That leap required different sequencing techniques, as well as new analytical approaches. "This project used cutting-edge software to assemble genomes and identify genetic variation, much of which simply did not exist a few years ago," co-author Charles Lee, a professor at the Jackson Laboratory for Genomic Medicine, told Live Science in an email. The sequencing techniques included one that generated long reads with very few errors and one that generated ultralong reads that were slightly more error-prone. At the expense of analyzing fewer genomes, this approach nonetheless enabled the second study to capture stretches of DNA that were totally missed in the first, Rodríguez-Martín said. Those "hidden" regions included the centromeres, important structures at the centers of chromosomes that are key for cell division. As a cell prepares to split, fibers attach to the centromeres and then pull the chromosome in two. The study found that, in about 7% of centromeres, there are likely two places where these fibers can attach, instead of only one. "Could that mean that those chromosomes are more unstable? Because if the spindle [fiber] attaches to two points, it might get confused," Korbel said. That's a purely speculative idea, he added, but it's one that can now be explored. The next step will be to study the effects of these centromere variations experimentally, Lee agreed. Issues with chromosome splitting can lead to various conditions. For example, "Down syndrome is the result of a mistake of chromosome segregation during cell division in meiosis," when cells split to form sperm and eggs, co-author Dr. Miriam Konkel, an assistant professor at the Clemson University Center for Human Genetics, told Live Science in an email. Like the first study, the second study also provided an unprecedented look at jumping genes, cataloging more than 12,900. Beyond cancer, jumping genes can also trigger various genetic diseases by causing mutations, as well as prompt more subtle changes in how genes are switched on and off, Konkel noted. A better understanding of the diversity of jumping genes can help unpack their function in human health and disease. Looking at both studies, scientists can now compare the newly sequenced genomes to other datasets that include both genome and health data, Korbel noted. This would be the first step toward linking the newfound structural variations to tangible health outcomes and, eventually, to incorporating those insights into medical practice. RELATED STORIES —Largest human family tree ever created retraces the history of our species —More than 150 'made-from-scratch' genes are in the human genome. 2 are totally unique to us. —As little as 1.5% of our genome is 'uniquely human' "Certain clinical studies will not be able to ignore these [sequencing] techniques because they will give them higher sensitivity to identify variation," Korbel said. "You don't want to miss variants." There's still more work to be done to improve the genomic data, as well, Lee added. More DNA could be incorporated from underrepresented populations, and the sequencing techniques and software could be further refined to make the process more efficient and accurate. But in the meantime, the pair of new studies marks a major technological feat. "These advanced tools were developed recently to handle the huge amounts of long-read data we are now using for each genome," Lee said. "A few years back, assembling a complete human chromosome from end to end, especially including centromeres, was virtually unattainable because the software and algorithms were not mature yet." Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
David Nabarro, British physician who led UN response to Ebola and COVID-19, dies
GENEVA (AP) — Dr. David Nabarro, a British physician who led the U.N. response to some of the biggest health crises in recent years, including bird flu, Ebola and the coronavirus pandemic, has died. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, confirmed Nabarro's death on social media platform X. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals,' Tedros wrote Saturday. 'His work touched and impacted so many lives across the world.' King Charles knighted Nabarro in 2023 for his contributions to global health after he served as one of six special envoys to the WHO on COVID-19. He won the 2018 World Food Prize for his work on health and hunger issues. He also was a candidate for the top job at the WHO in 2017 but lost out to Tedros in the final round of voting. Nabarro left the U.N. later that year. The 4SD Foundation, a social enterprise in Switzerland focused on mentoring the next generation of leaders in global sustainable development, said its strategic director died at his home Friday in a 'sudden passing.' Other details were not immediately available. 'David's generosity and unwavering commitment to improve the lives of others will be sorely missed,' the foundation wrote on its website Saturday. Survivors include his wife, Flo, as well as his five children and seven grandchildren. Solve the daily Crossword
